Efficacy and Safety of Morning Versus Evening Dose of Controlled-Release Simvastatin Tablets in Patients With Hyperlipidemia: A Randomized, Double-Blind, Multicenter Phase III Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sang-Hyun | - |
dc.contributor.author | Kim, Min-Kyung | - |
dc.contributor.author | Seo, Hong-Seok | - |
dc.contributor.author | Hyun, Min-Soo | - |
dc.contributor.author | Han, Kyoo-Rok | - |
dc.contributor.author | Cho, Seong-Wook | - |
dc.contributor.author | Kim, Young-Kwon | - |
dc.contributor.author | Park, Seong Hoon | - |
dc.date.accessioned | 2021-08-12T00:47:04Z | - |
dc.date.available | 2021-08-12T00:47:04Z | - |
dc.date.issued | 2013-09 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.issn | 1879-114X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13424 | - |
dc.description.abstract | Background: Flexibility in the recommended dosing time for a statin may improve patient compliance. Objective: This study was designed to compare the efficacy and tolerability of morning and evening doses of controlled-release simvastatin in Korean adults with dyslipidemia. It was carried out as a requirement to obtain authorization from the Korean regulatory agency to market the product. Methods: In this prospective, randomized, double-blind, multicenter, placebo-controlled Phase III study, we randomly assigned 132 patients with hypercholesterolemia to a morning-dose group or an evening-dose group. Patients in the morning-dose group received 20 mg controlled-release simvastatin in the morning and a placebo in the evening, and those in the evening-dose group received a placebo in the morning and 20 mg controlled-release simvastatin in the evening. Results: After 8 weeks of the treatment, the difference in the mean change of LDL-C between the morning-dose and evening-dose groups was -2.78% (95% confidence interval, -7.65 to 2.10). The changes in total cholesterol, triglycerides, HDL-C, apolipoprotein A1, apolipoprotein B, and lipoprotein (a) after treatment did not differ between groups. Also, the achievement rates of the target LDL-C goal suggested by the dyslipidemia treatment guideline of the Korean Society of Lipidology and Atherosclerosis were not different. No serious adverse event was observed in either group. Mild and moderate adverse events were observed similarly in both groups. Conclusions: Although controlled-release simvastatin significantly reduces LDL-C levels with good tolerability in Korean adults with dyslipidemia, the time of administration does not affect its efficacy. (C) 2013 Elsevier HS Journals, Inc. All rights reserved. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Excerpta Medica, Inc. | - |
dc.title | Efficacy and Safety of Morning Versus Evening Dose of Controlled-Release Simvastatin Tablets in Patients With Hyperlipidemia: A Randomized, Double-Blind, Multicenter Phase III Trial | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.clinthera.2013.06.020 | - |
dc.identifier.scopusid | 2-s2.0-84884354947 | - |
dc.identifier.wosid | 000325388600009 | - |
dc.identifier.bibliographicCitation | Clinical Therapeutics, v.35, no.9, pp 1350 - 1360 | - |
dc.citation.title | Clinical Therapeutics | - |
dc.citation.volume | 35 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1350 | - |
dc.citation.endPage | 1360 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | CORONARY-HEART-DISEASE | - |
dc.subject.keywordPlus | MEDICATION ADHERENCE | - |
dc.subject.keywordPlus | EVENTS | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | ATORVASTATIN | - |
dc.subject.keywordPlus | COMPLEXITY | - |
dc.subject.keywordPlus | REDUCTION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordAuthor | controlled-release formulation | - |
dc.subject.keywordAuthor | dyslipidemia | - |
dc.subject.keywordAuthor | simvastatin | - |
dc.subject.keywordAuthor | simvastatin administration and dosage | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.